Arca
Skip to content
Tools
Tools

IMPDH1: Inosine-5'-monophosphate dehydrogenase 1

Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on IMPDH1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Ribavirin

Phase 30

    Phase 21

    • Merimepodib

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      RibavirinBoxed warningApprovedBausch HealthSmall moleculeInhibitorInosine-5'-monophosphate dehydrogenase 1 inhibitor7
      MerimepodibPhase 2ViralClear Pharmaceuticals, Inc.Small moleculeInhibitorInosine-5'-monophosphate dehydrogenase 1 inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.
      Treatment of CKD Patients With HCVRibavirinPhase 2 / Phase 3Not yet recruitingTanta UniversityAug 18, 2026
      UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHFRibavirinPhase 2RecruitingLiverpool School of Tropical MedicineMar 6, 2025
      Assessing Antiviral Treatments in Early Symptomatic RSVRibavirinPhase 2RecruitingUniversity of OxfordJul 5, 2024
      LAssa Fever Adjunct Treatment With DEXamethasoneRibavirinPhase 2RecruitingBernhard Nocht Institute for Tropical MedicineJan 25, 2024
      ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyRibavirinPhase 2 / Phase 3RecruitingIrrua Specialist Teaching HospitalJan 18, 2024
      The Efficacy of Vosevi in Treating DAA-experienced PatientsRibavirin—RecruitingThe Third Affiliated Hospital of Guangzhou Medical UniversityDec 22, 2023
      Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Ribavirin—RecruitingDuke UniversityFeb 20, 2020

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Retinitis pigmentosa 10
      0.68
      Leber congenital amaurosis
      0.63
      Chronic hepatitis C virus infection
      0.60
      Hepatitis C virus infection
      0.60
      Leber congenital amaurosis 11
      0.60
      Cirrhosis of liver
      0.60
      Viral infectious disease
      0.46
      Crohn disease
      0.45
      Inherited retinal dystrophy
      0.42

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      IMPDH1

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1822, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P20839, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.